Nowotwory最新文献_第7页

[Anaplastic thyroid carcinoma]. [甲状腺间变性癌]。

Nowotwory Pub Date : 2020-02-10 DOI: 10.32388/9whjpw

Z. Sznapka, W. Bogacki, P. Bożek, J. Marjańska-Radziszewska, E. Obrapalska

引用次数: 20

Testicular dose contributed by X-ray volume image-(XVI)-guided intensity-modulated radiotherapy (IMRT) in prostate cancer patients 前列腺癌患者x射线体积成像(XVI)引导的调强放疗(IMRT)对睾丸剂量的贡献

Nowotwory Pub Date : 2020-01-01 DOI: 10.5603/NJO.2020.0012

D. Hempel, R. Chrenowicz, T. Filipowski, M. Wojtukiewicz, E. Sierko

{"title":"Testicular dose contributed by X-ray volume image-(XVI)-guided intensity-modulated radiotherapy (IMRT) in prostate cancer patients","authors":"D. Hempel, R. Chrenowicz, T. Filipowski, M. Wojtukiewicz, E. Sierko","doi":"10.5603/NJO.2020.0012","DOIUrl":"https://doi.org/10.5603/NJO.2020.0012","url":null,"abstract":"Introduction: To assess the dose received by testes during XVI-guided IMRT in prostate cancer patients (PCPs). Material and methods: Testes dose was calculated in 56 PCPs who underwent definitive IMRT using 6 MV or 15 MV photon energies. The dose was measured by thermoluminescent dosimeters (TLDs) MTS-N attached to the scrotum during the first three fractions of IMRT. Testicular concomitant exposure from XVI was measured using a PTW DIADOS E diagnostic dosimeter in ten randomly chosen patients. Results: The mean and standard deviation values of the average calculated testes dose was 123 ± 117 cGy comprising 1.6% of the prescribed total irradiation dose (Dt). A testicular dose measured by TLDs was 303 ± 110.5 cGy (4% of Dt) and depended on the distance from isocenter to testes (r = –0.8). From one XVI scan, the detected testicular mean dose was 4.3 mGy. Mean XVI scan numbers for all patients was 10.4 so mean concomitant dose in testes was 44.7 mGy (0.06% of Dt). Conclusions: Testicular dose may be significant in the aspect of fertility during IMRT in PCPs. Kilovoltage XVI-contributed dose to testes seems to be clinically negligible.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"18 1","pages":"47-53"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90095409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The authorship of research results and scientific publications in medical sciences 医学领域的研究成果和科学出版物的作者

Nowotwory Pub Date : 2020-01-01 DOI: 10.5603/NJO.2020.0017

Justyna Ożegalska-Trybalska

{"title":"The authorship of research results and scientific publications in medical sciences","authors":"Justyna Ożegalska-Trybalska","doi":"10.5603/NJO.2020.0017","DOIUrl":"https://doi.org/10.5603/NJO.2020.0017","url":null,"abstract":"Introduction. The article aims to present the rules for determining the authorship of research results and scientific publications under intellectual property law and the applicable standards. Materials and methods. The study is based on copyright law, national and international codes of ethical conduct in research and scientific publications, including the European Code of Conduct for Research Integrity and the guidelines for publication in medical journals of the International Committee of Medical Journal Editors. Results and discussion. The standards for the attribution of authorship to scientific results under intellectual property law, the applicable guidelines and customs are not consistent. Strict rules for determining the status of an author based on their creative contribution within the meaning of copyright law do not correspond in full extent to the needs of the sciences, where almost every contribution to research, clinical trials, and the preparation of publications is appreciated. In practice, this may create conflicting situations as to the proper identification and indication of authorship and co-authors. Conclusions. Among the standards for recognizing authorship, copyright standards prevail. A compromise solution between the restrictive approach for attributing authorship (co-authorship) of works under copyright and the non-binding recommendation of the ethical codes, is to distinguish between the ‘authors’ and other ‘non-authors’ who contributed to the creation of work, thereby protecting the interests of all parties involved.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"162 1","pages":"73-76"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86950251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjuvant radioiodine treatment in patients with thyroid cancer – current recommendations 甲状腺癌患者的辅助放射性碘治疗-目前的建议

Nowotwory Pub Date : 2020-01-01 DOI: 10.5603/NJO.2020.0015

A. Czarniecka, D. Handkiewicz-Junak

引用次数: 0

The atypical form of granulomatous lobular mastitis – diagnostic dilemmas: a case report 非典型肉芽肿性小叶性乳腺炎的诊断困境:1例报告

Nowotwory Pub Date : 2020-01-01 DOI: 10.5603/NJO.2020.0016

Andrzej Lorek, Wojciech Zarębski, Katarzyna Steinhof-Radwańska, M. Kajor, A. Boratyn-Nowicka, Joanna Lorek

引用次数: 1

Oncogeriatrics (part 5.) The role of comorbidities in older patients with cancer 老年肿瘤学(第5部分)合并症在老年癌症患者中的作用

Nowotwory Pub Date : 2020-01-01 DOI: 10.5603/NJO.2020.0013

Urszula Skorus, J. Kenig

{"title":"Oncogeriatrics (part 5.) The role of comorbidities in older patients with cancer","authors":"Urszula Skorus, J. Kenig","doi":"10.5603/NJO.2020.0013","DOIUrl":"https://doi.org/10.5603/NJO.2020.0013","url":null,"abstract":"Comorbidity is defined as the presence of one or more additional conditions co-occurring with primary indices. Comorbidity is common in older cancer patients. Its prevalence, however, is difficult to determine and varies by cancer site. There is no single reason for which comorbidity and cancer coexist, but chronic diseases and cancer are both common in older age and share many risk factors. There is no consensus on how should comorbidity be measured. Even though many comorbidity indices have been developed so far, no unified, widely used instrument exists. Patients with comorbidities have worse outcomes compared to those with no such conditions. They may experience diagnostic and therapeutic delay and be disqualified from radical treatment more often. Moreover, they are more likely to suffer from treatment-related complications and have worse overall survival. It seems important to assess the comorbidity status as a part of individualised oncologic treatment planning. However, as data regarding its significance are insufficient and in many cases conflicting, patients with comorbidity should not be routinely considered as not fit enough for a radical treatment. Therefore, to adequately address all of the concerns that have been raised, a broader participation of older, comorbid patients in clinical trials is needed.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"293 1","pages":"54-59"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77305141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Contouring of the left anterior descending coronary artery in patients with breast cancer – the radiation oncologist’s view 乳腺癌患者左冠状动脉前降支的轮廓——放射肿瘤学家的观点

Nowotwory Pub Date : 2020-01-01 DOI: 10.5603/NJO.2020.0014

M. Biedka, E. Żmuda

{"title":"Contouring of the left anterior descending coronary artery in patients with breast cancer – the radiation oncologist’s view","authors":"M. Biedka, E. Żmuda","doi":"10.5603/NJO.2020.0014","DOIUrl":"https://doi.org/10.5603/NJO.2020.0014","url":null,"abstract":"Breast cancer is the cancer with the largest prevalence, both in Poland and worldwide. The standard treatment in patients with this disease is breast-conserving therapy (BCT), followed by whole breast radiotherapy (WBRT) with a boost dose applied to the area of the bed created after tumour resection. In women who have undergone breast amputation – in the presence of poor prognostic factors – the chest wall is irradiated with or without the irradiation of the axillary fossa and clavicular area. Radiotherapy is used as an adjuvant treatment in connection with the high rate of relapses in the area of the treated breast – as much as 20% after 10 years. Some patients, before the commencement of the irradiation, are treated systemically with the use of regimens comprising drugs with a high degree of cardiotoxicity. This effect may even be increased during the course of radiotherapy – mainly in patients after amputation of the left breast. The side-effects induced by radiotherapy depend on area of the heart within the field of irradiation. Studies suggest that the vulnerable parts of the heart are the coronary vessels, and primarily, the left anterior descending (LAD) artery, which is located close to the chest wall. The objective of this study is to present practical guidelines concerning contouring the left anterior descending (LAD) artery in patients with cancer of the left breast, who have qualified for radiotherapy. Contouring the LAD seems to be significant as a method of assessing the critical organ during radiotherapy. The results may cause a modification of the treatment strategy: a change to the planned radiotherapy, the quantity of the beams and/or their angle of incidence or a change in the beam weight.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"75 1","pages":"60-64"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77047487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should perioperative chemotherapy in triple negative breast cancer routinely comprise platinum salts? A vote for no 三阴性乳腺癌围手术期化疗应常规使用铂盐吗?投反对票

Nowotwory Pub Date : 2019-12-31 DOI: 10.5603/njo.2019.0035

Joanna Kufel-Grabowska

引用次数: 0

Repair or perish – the role of p53 protein in a cell’s life 修复或消亡——p53蛋白在细胞生命中的作用

Nowotwory Pub Date : 2019-12-31 DOI: 10.5603/njo.2019.0031

Magdalena Kulesza, A. Dansonka-Mieszkowska, B. Pieńkowska-Grela

{"title":"Repair or perish – the role of p53 protein in a cell’s life","authors":"Magdalena Kulesza, A. Dansonka-Mieszkowska, B. Pieńkowska-Grela","doi":"10.5603/njo.2019.0031","DOIUrl":"https://doi.org/10.5603/njo.2019.0031","url":null,"abstract":"The p53 protein is one of the most important suppressors of neoplastic transformation. It regulates transcription of multiple genes and interacts directly with other proteins. It plays a significant role in the most important processes that take place in the cell, including: DNA repair, cell cycle and programmed cell death – apoptosis. Loss of its proper function leads to a disturbance of the mechanisms controlling cell proliferation and survival, which contributes to the development of neoplasms. The TP53 gene is called the guardian of the genome. Its mutations occur in a large percentage of tumors. They most often concern sequences that encode the DNA-binding domain (exons 5–8). The TP53 gene, together with the TP63 and TP73 genes, belongs to the oldest evolutionary family of cancer transformation suppressors. Its product, a full length p53 protein, consists of five domains and a flexible consolidator region and functions as a homotetramer. The regulation of p53 activity is caused by MDM2 protein, which contributes to proteasomal degradation of the suppressor. This review deals with the most important aspects of the regulation of cell activity by p53 protein. It describes the structure of p53 protein and the associated therapeutic possibilities.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"12 1-4 1","pages":"168-178"},"PeriodicalIF":0.0,"publicationDate":"2019-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72529353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Leopold Freund (1868–1943) & priority for X-ray therapy for benign disease 利奥波德·弗罗因德(1868-1943)&优先使用x射线治疗良性疾病

Nowotwory Pub Date : 2019-12-31 DOI: 10.5603/njo.2019.0033

R. Mould

引用次数: 0